Literature DB >> 36253977

Safflor yellow treating angina pectoris: A pharmacoeconomic evaluation and network meta-analysis.

Liang Lu1, Yang Li, Qiuchen Jin, Yongfa Chen.   

Abstract

BACKGROUND: Coronary heart disease (CHD) is a cardiovascular disease caused by myocardial ischemia. In China, safflor yellow and artemisinin-based combination therapies have been extensively used to treat angina pectoris.
METHODS: Efficacies were provided by a network meta-analysis following the PRISMA 2020 checklist. Cost-effectiveness analysis was based on patient perspectives. Two-way and probabilistic sensitivity analyses were conducted to assess the robustness of the study results.
RESULTS: Conventional treatment combined with safflower is a better choice against angina pectoris. Sensitivity analysis showed that the model was sensitive to the treatment efficacy rather than the drug cost.
CONCLUSION: Conventional treatment combined with safflower injection is suggested to treat angina pectoris. Low molecular weight heparin or compound Danshen-dropping pills can be used to increase the recovery rate of angina pectoris, according to conventional treatment combined with safflower injection.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36253977      PMCID: PMC9575819          DOI: 10.1097/MD.0000000000031036

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  5 in total

1.  [A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome].

Authors:  Qiong Zhang; Jian-Hua Peng; Xiang-nong Zhang
Journal:  Chin J Integr Med       Date:  2005-09       Impact factor: 1.978

2.  Economic Evaluation of Safflower Yellow Injection for the Treatment of Patients with Stable Angina Pectoris in China: A Cost-Effectiveness Analysis.

Authors:  Jianwei Xuan; Min Huang; Yongji Lu; Libo Tao
Journal:  J Altern Complement Med       Date:  2018-02-12       Impact factor: 2.579

3.  The prevalence of psychological distress by cancer site.

Authors:  J Zabora; K BrintzenhofeSzoc; B Curbow; C Hooker; S Piantadosi
Journal:  Psychooncology       Date:  2001 Jan-Feb       Impact factor: 3.894

4.  Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019.

Authors:  Saeid Safiri; Nahid Karamzad; Kuljit Singh; Kristin Carson-Chahhoud; Cobi Adams; Seyed Aria Nejadghaderi; Amir Almasi-Hashiani; Mark J M Sullman; Mohammad Ali Mansournia; Nicola Luigi Bragazzi; Jay S Kaufman; Gary S Collins; Ali-Asghar Kolahi
Journal:  Eur J Prev Cardiol       Date:  2022-03-11       Impact factor: 7.804

5.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.